Redhill Biopharma (RDHL) Stock Price, News & Analysis

Company Overview

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health. Its development pipeline includes Bekinda® (RHB-102), an ondansetron formulation for the treatment of acute gastroenteritis and irritable bowel syndrome with diarrhea, which has completed pivotal trials and is under regulatory review. In addition, RedHill is evaluating RHB-204, a liposomal formulation targeting pulmonary nontuberculous mycobacterial infections, and RHB-107, a serine protease inhibitor being explored in oncology indications.

With research and development activities spanning North America, Europe and Israel, RedHill maintains offices in Tel Aviv and a U.S. subsidiary in Raleigh, North Carolina. The company leverages contract research organizations and clinical sites across multiple geographies to advance its candidates through Phase III studies. RedHill’s business development efforts have yielded strategic licensing and distribution partnerships to support commercial launches and broaden market access for its products.

RedHill is led by Chief Executive Officer Amir Reichman, who brings experience in biopharmaceutical development and commercialization to the company’s operations. Under his leadership, the management team and board of directors are committed to executing on late-stage clinical programs, securing regulatory approvals and building commercial infrastructure to support patient access to novel therapies.

Key Stats

• Today's Range: $0.96 to $1.02
• 50-Day Range: $0.74 to $1.09
• 52-Week Range: $0.71 to $3.31
• Volume: 19,083 shs
• Average Volume: 62,164 shs
• Market Capitalization: $5.19 million
• P/E Ratio: 0.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Redhill Biopharma Stock Analysis - MarketRank™

Redhill Biopharma scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Redhill Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Redhill Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Redhill Biopharma is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.85.

Price to Earnings Ratio vs. Sector

The P/E ratio of Redhill Biopharma is 0.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.88.

Price to Book Value per Share Ratio

Redhill Biopharma has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.15% of the float of Redhill Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Redhill Biopharma has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Redhill Biopharma has recently decreased by 63.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Redhill Biopharma does not currently pay a dividend.

Dividend Growth

Redhill Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Redhill Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.81% of the stock of Redhill Biopharma is held by insiders.

Percentage Held by Institutions

7.20% of the stock of Redhill Biopharma is held by institutions.

Company Calendar

• Last Earnings: 11/30/2021
• Today: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RDHL
• Previous Symbol: ASX:RDH
• CIK: 1553846
• Web: www.redhillbio.com
• Phone: 972-3541-3131
• Fax: 972-3541-3144
• Employees: 210
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.34
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $290 thousand
• Price / Sales: 17.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 5,190,000
• Free Float: 4,837,000
• Market Cap: $5.19 million
• Optionable: No Data
• Beta: 5.05